Enzymatica AB (OSTO:ENZY) EBIT: kr-43.93 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ENZY Enzymatica AB OSTO:ENZY
58 GF Score
Price kr1.85
GF Value kr2.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Enzymatica AB EBIT?

Enzymatica AB OSTO:ENZY -0.27% 58 EBIT is kr-43.93 Mil as of Jun. 2026. GuruFocus rates OSTO:ENZY with a GF Score™ of 58/100 and a GF Value™ of kr2.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Enzymatica AB's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was kr-12.41 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-43.93 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Enzymatica AB's annualized ROC % for the quarter that ended in Jun. 2026 was -49.21%. Enzymatica AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -149.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Enzymatica AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -9.79%.


Enzymatica AB  (OSTO:ENZY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Enzymatica AB's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=-50.552 * ( 1 - 0% )/( (95.873 + 109.586)/ 2 )
=-50.552/102.7295
=-49.21 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Enzymatica AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-49.628/( ( (9.719 + max(16.749, 0)) + (22.943 + max(16.919, 0)) )/ 2 )
=-49.628/( ( 26.468 + 39.862 )/ 2 )
=-49.628/33.165
=-149.64 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.417 + 16.469 + 0) - (6.137 + 0 + 0)
=16.749

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.35 + 14.47 + 0) - (1.901 + 0 + 0)
=16.919

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Enzymatica AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=-43.931/448.868
=-9.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymatica AB EBIT Related Terms


Enzymatica AB EBIT Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB EBIT Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44.81 -67.75 -47.63 -51.62 -51.77

Enzymatica AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.35 -8.15 -10.14 -13.24 -12.41

OSTO:ENZY vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's EV-to-EBIT falls into.


OSTO:ENZY
58GF Score
Enzymatica AB OSTO:ENZY
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-43.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-43.93 Mil mean?
Enzymatica AB (OSTO:ENZY) has a EBIT of kr-43.93 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Enzymatica AB.
Is Enzymatica AB's EBIT too high?
Enzymatica AB's current EBIT is kr-43.93 Mil. Overall, Enzymatica AB has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's EBIT compare to ZTS?
Enzymatica AB's EBIT of kr-43.93 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Enzymatica AB. Enzymatica AB's current EBIT is kr-43.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (OSTO:ENZY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.13, compared to a current price of kr1.85 — trading 13.4% below its estimated fair value. The current EBIT is kr-43.93 Mil. Enzymatica AB's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Enzymatica AB (OSTO:ENZY), the current EBIT is kr-43.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (OSTO:ENZY) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued. The current stock price of kr1.85 is trading 13.4% below its estimated GF Value™ of kr2.13. GuruFocus considers Enzymatica AB to be Modestly Undervalued.

Key valuation signals for OSTO:ENZY:

  • EBIT: kr-43.93 Mil
  • GF Value™: kr2.13 vs. price of kr1.85 (13.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the OSTO:ENZY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enzymatica AB Business Description

Other Exchanges EN9:Germany
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score

Get the complete analysis for OSTO:ENZY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.85
Price
kr2.13
GF Value